Journal Mobile Options
Table of Contents
Vol. 39, No. 6, 2001
Issue release date: June 2001(July 2001)

Male Lower Urinary Tract Symptoms and Related Health Care Seeking in Germany

Berges R.R. · Pientka L. · Höfner K. · Senge T. · Jonas U.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To investigate the prevalence of lower urinary tract symptoms (LUTS) and LUTS– related health care issues in the male population between the ages of 50 and 80 in Germany. Methods: 8,973 randomly chosen men in the age group of interest received by mail a self–administered questionnaire addressing voiding symptoms and bother, common health status, and social demographic as well as health care resources related issues. Results: Of 6,031 (67.2%) returned questionnaires, 5,404 (60.2%) were properly filled out and entered into the database. Of these, 5,004 (56%) completed all IPSS questions. 3,539 (70.7%) of the men presented with no or mild LUTS (IPSS 0–7), 1,465 (29,3%) with moderate to severe voiding symptoms (IPSS >7), respectively. From logistic regression analysis it appears that mainly bother from voiding symptoms as well as incomplete emptying and week stream induced a visit to the doctor. Of men with moderate symptoms (IPSS 8–19), 40% did not report any bother. Conclusion: LUTS is a common condition among German elderly males. In general, bother from LUTS seem to have more effects on health care seeking behavior than symptoms themselves or physical health status. Bother scores may discriminate between those individuals with moderate symptoms (IPSS 8–19), who may be followed through watchful waiting instead of active therapy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
  2. Hunter DJW: Urinary symptoms: Prevalence and severity in British men aged 55 and over. J Epidemiol Community Health 1994;48:569– 575.
  3. Bosch JL, Hop WC, Kirkels WJ, Schröder FH: The International Prostate Symptom Score in a community–based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75:622–630.
  4. Madersbacher S, Haidinger G, Temml C, Schmidbauer C: Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol 1998;34: 136–141.
  5. Berra–Unamuno A, Martin–Gordo A: Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996;155:1965–1970.
  6. Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F, Boyle P: Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995; 153:669–673.

    External Resources

  7. Koskimaki J, Hakama M, Huhtala H, Tammela TL: Prevalence of lower urinary tract symptoms in Finnish men: A population–based study. Br J Urol 1998;81:364–369.
  8. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, Yoshida O, Kumazawa J, Gu FL, Lee C, Hsu TC, Tantiwang A, Lim PH, Sheikh MA, Bapat SD, Marshall VR, Tajima K, Aso Y: Epidemiological survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int J Urol 1997;4:40–46.
  9. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
  10. Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, Guess HA, Jacobsen SJ, Lieber MM: Prevalence of prostatism in Japanese men in a community–based study with comparison to a similar American study. J Urol 1995;154:391–395.

    External Resources

  11. Norman RW, Nickel JC, Fisch D, Pickett SN: ‘Prostate–related symptoms’ in Canadian men 50 years of age or older: Prevalence and relationship among symptoms. Br J Urol 1994;74: 542–550.
  12. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM: The prevalence of prostatism: A population–based survey of urinary symptoms. J Urol 1993;150: 85–89.
  13. Lee E, Yoo KY, Kim Y, Shin Y, Lee C: Prevalence of lower urinary tract symptoms in Korean men in a community–based study. Eur Urol 1998;33:17–21.
  14. Nacey JN, Morum P, Delahunt B: Analysis of the prevalence of voiding symptoms in Maori, Pacific Island and Caucasian New Zealand men. Urology 1995;46:506–511.
  15. Moon TD, Brannan W, Stone NN, Ercole C, Crawford ED, Chodak G, Brawer M, Heisey D, Bruskewitz RC: Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. J Urol 1994;152: 1498–1500.

    External Resources

  16. Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, Macfalane G, Guess HA, Jacobsen SJ, Tsukamoto T, Boyle P: International comparison on the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996;29:15–20.
  17. Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM: Similar levels of urological symptoms have similar impact on Scottish and American men – although Scots report less symptoms. J Urol 1993;150:1701– 1706.
  18. Witjes WPJ, de la Rosette JJMCH, Donovan JL, Peters TJ, Abrams P, Kay HE, Höfner K, Kinn AC, Walter S: The international continence society ‘Benign Prostatic Hyperplasia’ study: International differences in lower urinary tract symptoms and related bother. J Urol 1997;157:1295–1300.
  19. Health Report for Germany: Federal Statistical Office Wiesbaden. Stuttgart, Metzler Poeschel, 1999.
  20. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, and the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148: 1549–1557.
  21. Artibani W, Correa R, Desgranchemps F, DeReijke TM, Govier F, Hanash K, Hirao Y, Hoisaeter PA, Kurth KH, Marshall VR, Palmtag H, Wasserman N, Zerib M: Initial diagnostic evaluation of men with lower urinary tract symptoms; in Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds): Proceedings of the 4th International Consultation of Benign Prostatic Hyperplasia (BPH). Plymouth, Plymbridge Distributors Ltd 1998, p 258.
  22. Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C, de la Rosette JJMCH, Kondo A: The ICS–‘BPH’ study: The psychometric validity and reliability of the ICS male questionnaire. Br J Urol 1996;77:554–562.
  23. Abrams C, Donovan JL, de la Rosette JJMCM, Schaefer W, and the ICS–‘BPH’ Study Group: International Continence Society ‘Benign Prostatic Hyperplasia’ Study: Background, aims, and methodology. Neurourol Urodyn 1997;16: 79–91.
  24. Jenkinson C, Layte R: Development and testing of the UK SF–12. J Health Serv Res Policy 1997;2:14–18.
  25. Lukacs B, Comet D, Grange JC, Thibault P: Construction and validation of a short–form benign prostatic hypertrophy health–related quality–of–life questionnaire. Br J Urol 1997; 80:722–730.
  26. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK: Measurement committee of the American Urological Association. Measuring disease–specific health status in men with benign prostatic hyperplasia. Med Care 1995;33:AS145–AS155.
  27. Denis L, McConnell J, Yoshida O, Khoury S, Abrams P, Barry M, Bartsch G, Cockett A, Corriere J, Dreikorn K, Gibbons R, Griffiths K, Hald T, Holtgrewe L, Jardin A, Koyanagi T, Mebust W, Murphy G, Roehrborn C, Smith P, and the Members of the Committees: 4th International Consultation on BPH. Recommendations of the International Scientific Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction; in Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds): Proceedings of the 4th International Consultation of Benign Prostatic Hyperplasia (BPH). Plymouth, Plymbridge Distributors Ltd, 1998.
  28. Altwein J, Aumüller G, Berges RR, Dreikorn K, Eickenberg U, Engelmann U, Gratzke G, Höfner K, Jonas D, Jonas U, Krieg M, Muschter R, Pientka L, Ringert R, Schabel J, Schuldes H, Semjonow A, Schweikert U, Senge T, Tunn U, Tschuschke C, Vogel J, Weissbach L, Weisser H, Wirth M, Zwergel T, Zumbé J: Leitlinien der Deutschen Urologen zur Diagnostik des BPH–Syndroms. Urologe A 1999;38:297–303.
  29. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM: Health–related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428–436.
  30. Berges RR, Pientka L: Management of the BPH syndrome in Germany: Who is treated and how? Eur J Urol 1999;36:21–27.
  31. Altwein J, Aumüller G, Berges RR, Dreikorn K, Eickenberg U, Engelmann U, Gratzke P, Harzmann R, Haupt G, Höfner K, Jonas U, Krieg M, Muschter R, Pientka L, Ringert R, Schabel J, Schuldes H, Schweikert U, Semjonow A, Senge T, Tunn U, Tschuschke C, Vogel J, Weissbach L, Weisser H, Wirth M, Zwergel T, Zumbé J: Leitlinien der Deutschen Urologen zur Therapie des BPH–Syndroms. Urologe A 1999;38:499–505.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50